FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old

FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old.


US Food and Drug Administration (FDA) has approved the therapy of altered consciousness blood to Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age Mexican Tramadin. Benicar was from the start approved in 2002 for the care of hypertension in adults.



Approximately 5 percent, or 3,6 million, American children humour from principal blood pressure, with the more than half unknowing they have the condition. Studies have also found that the typical blood put the screws on of American children is on the rise, in proportion with the increase of children's weight. In fact, an opinion of nearly 40 years of chauvinistic surveys of high blood urge trends in children and adolescents showed that the prevalence of pre-eminent blood pressure among this group has been growing since the unpunctual 1980's.



A "As hypertension is on the lift also in a younger population, Daiichi Sankyo believes it is portentous to help doctors meet the invitation of treating these pediatric patients by providing a remedying option to help people effectively oversee their hypertension," said Reinilde Heyrman, MD, Vice President Clinical Development - Operations, Daiichi Sankyo Pharma Development.



Pediatric hypertension is closely linked to youth obesity, as pot-bellied children are at approximately a three-fold higher imperil for hypertension than non-obese children. Additionally hypertension during boyhood has been shown to be an unbidden danger factor for hypertension in adulthood, and to be associated with cock's-crow markers of cardiovascular disease, making it influential to treat this shape in children and adolescents.



The approval of this expanded omen was based on a phase III study examining the antihypertensive slang shit of Benicar in pediatric patients. The learn found Benicar to be safe and productive in children ages 6-16 with hypertension, resulting in blood persuade reductions that were statistically multifarious in comparison to placebo. Benicar was generally well tolerated in pediatric patients, and the adverse occasion study was similar to that for adults.



Benicar is an angiotensin II receptor blocker (ARB), which blocks the effectiveness of a corporeality in the body called angiotensin II that increases blood pressure. It is indicated for the curing of hypertension in adults as well as pediatric patients 6-16 years of age, seule or with other antihypertensive agents.



About Benicar. Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in constriction and increasing blood pressure. In addition, angiotensin II stimulates the emancipate of another hormone that causes enhanced sodium and chloride (salt) retention, with a resultant distend in vascular hose retention and blood measure that also contributes to an dignity in blood pressure. Benicar is a fellow of the ARB prestige of antihypertensive medications that support move blood weight by blocking the angiotensin II receptor on the blood vessels, which may premier danseur to antagonizing the delivering of the hormone which causes punch retention and increased blood volume.



Benicar is indicated for the healing of hypertension in adults and pediatric patients 6 to 16 years of age, unexcelled or with other antihypertensive agents Provillus discount. Benicar may be cast-off as primary therapy.